Emerging treatments for major depression

References

• Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat. Neurosci.2(Suppl.), 1068–1070 (2002).
   Google Scholar
• Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharmaceut. Design11, 145–155(2005).
   PubMed Web of Science ®Google Scholar
• Wong DT. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp. Opin. Invest. Drugs7, 1–9 (1998).
   PubMedGoogle Scholar
• Kasamo K, Blier P, de Montigny C. Blockade of serotonin and norepininephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J. Pharm. Exp. Ther.277, 278–286 (1996).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropharmacol.25, 871–880 (2001).
   Google Scholar
• Engleman ES, Perry KW, Mayle DA, Wong DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropharmacol.12, 287–295 (1995).
   Google Scholar
• Turcotte JE, Debonnel G, de Montigny C, Herbert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropharmacol.24, 511–521 (2001).
   Google Scholar
• Vincent S, Bieck PR, Garland EM et al. Clinical assessment of norepinephrine transporter blockade throughy biochemical and pharmacological profiles. Circulation109, 3202–3207 (2004).
   PubMed Web of Science ®Google Scholar
• Berk M, Du Pleiss AD, Birkett M et al. An open label study of duloxetine hydrochloride, a mixed 5-HT and noradrenaline re-uptake inhibitor, in patients with major depressive disorder. Int. Clin. Psychopharmacol.12, 137–140 (1997).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt CH, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiat.63, 225–231 (2002).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60mg once daily for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiat.63, 308–315 (2002).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily dosing versus placebo in the acute management of major depression. J. Psychiat. Res.36, 383–390 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ. Duloxetine in the treatment of depression. A double- blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol.24, 389–399 (2004).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. NeuroPsychopharmacol.14, 457–470 (2004).
   PubMed Web of Science ®Google Scholar
• Burt V, Wohlreich MM, Mallinckrodt CH et al. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics46, 345–354 (2005).
   PubMed Web of Science ®Google Scholar
• Raskin J, Goldstein DJ, Mallinckrodt CH et al. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiat.64, 1237–1244 (2003).
   PubMed Web of Science ®Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacol.20, 327–341 (2005).
   PubMed Web of Science ®Google Scholar
• Depreux P, Lesieur D, Mansour HA et al. Synthesis and structure–activity relationships of novel naphthalenic and bioisoteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem.37, 3231–3239 (1994).
   PubMed Web of Science ®Google Scholar
• Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem.35, 1484–1486 (1992).
   PubMed Web of Science ®Google Scholar
• Conway S, Canning SJ, Howell E et al. Characterization of human melatonin Mt1 and MT2 receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol.390, 15–24 (2000).
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. Dose-dependent effects of S20098, a melatonin agonist on direction of reentrainment of rat circadian rhythms. Psychopharmacol118, 385–390 (1995).
   PubMed Web of Science ®Google Scholar
• Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome. Pharmacol. Biochem. Behav.46, 45–49 (1993).
   PubMed Web of Science ®Google Scholar
• Chagraoui A, Protais P, Filloux T, Mocaer E. Agomelatine (S20098) antagonizes the penile erections induced by the stimulation of 5HT2C receptors in Wistar rats. Psychopharmacol.170, 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharm. Exp. Ther.306, 954–964 (2003).
   PubMed Web of Science ®Google Scholar
• Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiat. Neurosci.29, 126–133 (2004).
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. NeuroPsychopharmacol.28, 694–703 (2003).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melanotergic and serotonergic properties: role of 5HT2C receptor blockade Psychopharmacol177, 1–12 (2005).
   Web of Science ®Google Scholar
• Loo H, Dalery J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin agonist and selective 5HT2C receptor antagonist, in the treatment of major depressive disorders. L’Encephale29, 165–171 (2003).
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5HT2C antagonist, in the treatment of major depressive disorder: a placebo controlled dose range study. Int. Clin. Psychopharmacol.17, 239–247 (2002).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, Leyoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled, discontinuation study. Int. Clin. Psychopharmacol.19, 271–280 (2004)
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). Eur. NeuroPsychopharmacol.15(Suppl. 3), S435 (2005).
   PubMed Web of Science ®Google Scholar
• Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol.21(Suppl. 1), S25–S29 (2006).
   PubMed Web of Science ®Google Scholar
• Rogoz Z, Skuza G, Kllodzinska A. Anxiolytic and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 agonist, in rats. Pol. J. Pharmacol.56, 519–526 (2004).
   PubMedGoogle Scholar
• Corrigan MH, Denahan AQ, Wright CE et al. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress. Anxiety11, 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry.56, 54–60 (2004).
   PubMed Web of Science ®Google Scholar
• Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry12, 137–140 (2000).
   PubMedGoogle Scholar
• Perugi G, Toni C, Ruffolo G et al. Adjunctive dopamine agonists in treatment – resistant bipolar-II depression: an open case series. Pharmacopsychiatry34, 137–141 (2001).
   PubMed Web of Science ®Google Scholar
• Lattanzi L, Dell’Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord.4, 307–314 (2002).
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment resistant depression an extended follow-up. Depress. Anxiety20, 131–138 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety7(Suppl. 1) 11–17 (1998).
   PubMedGoogle Scholar
• Gupta RK, Tiller JWG, Burrows GD. Dual action antidpressants and some important considerations. Aust. NZ J. Psychiat.37, 190–195 (2003).
   PubMed Web of Science ®Google Scholar
• Briley M. New hope in the treatment of painful symptoms in depression. Curr. Opin. Invest. Drugs4, 42–45 (2003).
   PubMedGoogle Scholar
• DeBoer T, Nefkens F, van Helvoirt A. The α2-adrenoceptor antagonist Org3770 enhances noradrenergic and 5HT1A mediated serotonergic neurotransmission in vivo.Eur. J. Pharmacol.253, R5–R6 (1994).
   Google Scholar
• Olver JS, Burrows GD, Norman TR. Third generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs15, 941–954 (2001).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F et al. S33005, a novel ligand at both serotonin and norepinephrine transporters I: receptor binding, electrophysiological and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J. Pharm. Exp. Ther.298, 565–580 (2001).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Dekeyne A, Papp M et al. S33005, a novel ligand at both serotonin and norepinephrine transporters II: behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J. Pharm. Exp. Ther.298, 581–591 (2001).
   PubMedGoogle Scholar
• Cespuglio R, Rousset C, Debilly G et al. Acute administration of the novel serotonin and noradrenaline reuptake inhibitor S33005, markedly modifies sleep–wake cycle architecture in the rat. Psychopharmacol.181, 639–652 (2005).
   Google Scholar
• Board F, Persky H, Hamburg DA. Psychological stress and endocrine functions, Psychosomaticsic Med.18, 324–333 (1956).
   PubMed Web of Science ®Google Scholar
• Gibbons JL. Cortisol secretion rate in depressive illness. Arch. Gen. Psychiat.10, 572–575 (1964).
   PubMed Web of Science ®Google Scholar
• Mitchell P, Hadzi-Pavlovic D, Parker G et al. Depressive psychomotor disturbance, cortisol and dexamethasone. Biol. Psychiat.40, 941–950 (1996).
   PubMed Web of Science ®Google Scholar
• Arborelius L, Owens MJ, Plotsky PM et al. The role of corticotrophin releasing factor in depression and anxiety disorders. J. Endocrinol.160, 1–12 (1999).
   PubMed Web of Science ®Google Scholar
• Deuschle M, Schweiger U, Weber B et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J. Clin. Endocrinol. Metab.82, 234–238 (1997).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Widerlov E, Bisette G et al. Elevated concentrations of CSF corticotrophin releasing factor-like immunoreactivity in depressed patients. Science226, 1342–1344 (1984).
   PubMed Web of Science ®Google Scholar
• McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br. J. Psychiat.177, 390–395 (2000).
   PubMed Web of Science ®Google Scholar
• Ravaris CL, Sateia MJ, Beroza KW et al. Effect of ketoconazole on a hypophysectomised, hypercortisolaemic, psychotically depressed woman. Arch. Gen. Psychiat.45, 966–967 (1988).
   PubMed Web of Science ®Google Scholar
• Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology22(Suppl. 1), S125–S132 (1997).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Chan T et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psychiat.45, 1070–1074 (1999).
   PubMed Web of Science ®Google Scholar
• Malison RT, Anand A, Pelton GH et al. Limited efficacy of ketoconazole in treatment refractory major depression. J. Clin. Psychiat.19, 466–470 (1999).
   Google Scholar
• Murphy BE, Filipini D, Ghadirian AM. Possible use of the glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU486. J. Psychiat. Neurosci.18, 209–213 (1993).
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Flores BH, Kalezhan M et al. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol.21, 516–521 (2001).
   PubMed Web of Science ®Google Scholar
• Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med.7, 605–611 (2001).
   PubMed Web of Science ®Google Scholar
• Gilligan PJ, Robertson DW, Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem.43, 1641–1660 (2000).
   PubMed Web of Science ®Google Scholar
• Lelas S, Wong H, Li Y-W et al. Anxiolytic-like effects of the corticotrophin- releasing factor 1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl- 8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J. Pharm. Exp. Ther.309, 293–302 (2004).
   PubMed Web of Science ®Google Scholar
• Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 antagonist. Eur. J. Pharmacol.323, 21–26 (1997).
   PubMed Web of Science ®Google Scholar
• Arborelius L, Skelton KH, Thrivikraman KV et al. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharm. Exp. Ther.294, 588–597 (2000).
   PubMed Web of Science ®Google Scholar
• Hoyberg J, Wik G, Mehtonen OP et al. ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int. J. NeuroPsychopharmacol.5(Suppl. 1), 148 (2002).
   Google Scholar
• Zobel AW, Nickel T, Kunzel HEM. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiat. Res.34, 171–181 (2000).
   PubMed Web of Science ®Google Scholar
• Rupniak N, Kramer MS. Substance P and related tachykinins. In: Neuropsychopharmacology The Fifth Generation of Progress. Davis KL, Charney D, Coyle JT, Nemeroff CB (Eds). American College of Neuropsychopharmacology 171–177 (2002).
   Google Scholar
• Mantyh PD. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiat.63(Suppl. 1), 6–10 (2002).
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science281, 1640–1645 (1998).
   PubMed Web of Science ®Google Scholar
• Krishnan KRR. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiat.63(Suppl. 1), 25–29 (2002).
   PubMedGoogle Scholar
• Gold PW, Goodwin FK, Reus VI. Vasopressin in affective illness. Lancet1, 1233–1236 (1978).
   PubMed Web of Science ®Google Scholar
• van Louden L, Goekoop JG, van Kempen GM et al. Plasma levels of arginine vasopressin elevated in patients with major depression, NeuroPsychopharmacol.17, 284–292 (1997).
   PubMed Web of Science ®Google Scholar
• de Winter RF, van Hemert AM, DeRijk RH et al. Anxious-retarded depression: relation to plasma vasopressin and cortisol. NeuroPsychopharmacol.28, 140–147 (2003).
   PubMed Web of Science ®Google Scholar
• De Bellis MD, Gold PW, Geracioti TD et al. Association of fluoxetine treatment with reductions in CSF concentrations of corticotrophin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiat.150, 656–657 (1993).
   PubMed Web of Science ®Google Scholar
• Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des.11, 205–225 (2005).
   PubMed Web of Science ®Google Scholar
• Ebner K, Wotjak CT, Holsboer F et al. Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur. J. Neurosci.11, 997–1002 (1999).
   PubMed Web of Science ®Google Scholar
• Ebner K, Wotjak CT, Landgraf R et al. Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats, Eur. J. Neurosci.15, 384–388 (2002).
   PubMed Web of Science ®Google Scholar
• Serradeil–Le Gal C, Derick S, Brossard G et al. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress6, 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Tanoue A, Ito S, Honda K et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest.113, 302–309 (2004).
   PubMed Web of Science ®Google Scholar
• Griebel G, Simiand J, Stemmelin J et al. The vasopressin V1b receptor as a therapeutic target in stress related-related disorders. Curr. Drug Target CNS Neurol. Disord.2, 191–200 (2003).
   PubMedGoogle Scholar
• Griebel G, Simiand J, Serradeil-Le Gal C et al. Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist SSR149415 suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl Acad. Sci. USA99, 6370–6375 (2002).
   PubMed Web of Science ®Google Scholar
• Nowak G, Trullas R, Layer RT et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocycloprpane carboxylic acid. J. Pharm. Exp. Ther.265, 1380–1386 (1993).
   PubMed Web of Science ®Google Scholar
• Paul IA, Layer RT, Skolnick P et al. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol.247, 305–311 (1993).
   PubMed Web of Science ®Google Scholar
• Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol.375, 31–40 (1999).
   PubMed Web of Science ®Google Scholar
• Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids23, 153–159 (2002).
   PubMed Web of Science ®Google Scholar
• Pacher P, Kecskemeti V. Trends in the development of new antidepressants: is there light at the end of the tunnel? Curr. Med. Chem.11, 925–943 (2004).
   PubMed Web of Science ®Google Scholar
• Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci.71, 2921–2937 (2002).
   PubMed Web of Science ®Google Scholar
• Stogner KA, Holmes PV. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol.387, R9–R10 (2000).
   Web of Science ®Google Scholar
• Qu D. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature380, 243–247 (1996).
   PubMed Web of Science ®Google Scholar
• Sato Y. Molecular characterization of the melanin-concentrating-hormone receptor. Nature400, 265–269 (1999).
   PubMed Web of Science ®Google Scholar
• Borowsky B, Durkin MM, Ogozalek K et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med.8, 825–830 (2002).
   PubMed Web of Science ®Google Scholar
• Duman RS. Depression: a case of neuronal life and death? Biol. Psychiat.56, 140–145 (2004).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Rev.45, 104–114 (2004).
   PubMedGoogle Scholar
• Shirayama Y, Chen ACH, Nakagawa DS et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J. Neurosci.22, 3251–3261 (2002).
   PubMed Web of Science ®Google Scholar
• Siuciak JA, Lewis DR, Wiegand RM et al. Antidepressant like effect of brain derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav.56, 131–137 (1997).
   PubMed Web of Science ®Google Scholar